Parallel Advisors’s Vor Biopharma VOR Stock Holding History

Parallel Advisors’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$92	Sell	5 -43	-90%	-$651	﹤0.01%	3880
2026 Q1	$856	Buy	+48	New	+$677	﹤0.01%	3566
2022 Q1	–	Sell	-25	Closed	-$6K	–	3292
2021 Q4	$6K	Buy	25 +21	+525%	+$6.05K	﹤0.01%	2354
2021 Q3	$1K	Buy	4 +2	+100%	+$595	﹤0.01%	2975
2021 Q2	$1K	Buy	+2	New	+$987	﹤0.01%	2842

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Parallel Advisors's VOR Position: Q2 2026 in Review

Parallel Advisors reduced its Vor Biopharma (VOR) stake by 90% in Q2 2026, selling an estimated $651 and leaving 5 shares worth $92. The position accounts for ﹤0.01% of the portfolio, ranked #3880.

Parallel Advisors first reported a position in VOR in Q2 2021 and has held it in 5 quarters since. The position peaked at $6K in Q4 2021. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Parallel Advisors held 5 shares of Vor Biopharma worth $92 as of Q2 2026.
Parallel Advisors sold 43 Vor Biopharma shares in Q2 2026, an estimated $651.
Vor Biopharma made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3880 holding.
Parallel Advisors first reported a position in Vor Biopharma in Q2 2021 and has held it in 5 quarters since.
Parallel Advisors's Vor Biopharma position peaked at $6K in Q4 2021.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.